Drugs / GSK2018682
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01466322 | Dec 2010 → Feb 2011 | relapsing-remitting multiple sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01387217 | May → Dec 2010 | multiple sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01431937 Comparator | Oct 2010 → Mar 2011 | relapsing-remitting multiple sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2018682 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01387217 ↗ |
| Action | Inhibit | “measuring the inhibitory effect of GSK2018682 on total lymphocyte counts.” NCT01387217 ↗ |
| Modality | Small molecule | — CHEMBL4297542 ↗ |
| Route | Oral | “each regimen A,B C or D will be administered orally” NCT01466322 ↗ |